Clinical Trials Logo

Therapeutic Agent Toxicity clinical trials

View clinical trials related to Therapeutic Agent Toxicity.

Filter by:
  • None
  • Page 1

NCT ID: NCT04400786 Recruiting - Clinical trials for Ankylosing Spondylitis

A Randomized Open-labeled Study for Comparing Methods of Using Imrecoxib to Treat AS

Start date: May 7, 2020
Phase: N/A
Study type: Interventional

The selective cox-2 inhibitor has been widely used in the treatment of Ankylosing spondylitis (AS). The Imrecoxib is a new cox-2 inhibitor. But the treatment strategy has not been decided yet. To determine which is better in treating AS in the methods between on-demand treatment and continuous treatment. To solve this question, we designed this study.

NCT ID: NCT02957864 Recruiting - Hiv Clinical Trials

Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide

BACTAF
Start date: October 2016
Phase: Phase 4
Study type: Interventional

Tenofovir disoproxil fumarate (TDF) is one of the most frequently used drugs to treat HIV. Long term use of TDF can induce renal toxicity. Tenofovir alafenamide (TAF) is a new pro-drug of Tenofovir which has not been associated with renal toxicity and may therefore be a good substitute for TDF in patients with TDF induced renal toxicity. Abacavir (ABC) is another drug that can be used for the treatment of HIV and is not associated with renal toxicity. In this study the investigators will compare the effect on renal function of a switch from TDF to TAF with a switch from TDF to ABC in patients with TDF induced renal insufficiency.